Site Number:	Physician Last Name: Dr			
Date://20	Medidata Subject ID:			
IRONMAN Physician Questionnaire				
This survey has been designed to understand how physicians choose and discontinue treatments for men with advanced prostate cancer.				
The questionnaire has two sections:				
Section 1: Treatment d	liscontinuation (pages 2–4)			
Section 2: New treatme	ent initiation (pages 5–6)			
Please mark the box(es) X that best describe your choice(s).				
Please do not forget to fill out	the identifiers on top of each page.			
Your contribution to the IRON	IMAN Registry is much appreciated.			

All rights reserved. No re-use without explicit written permission by the IRONMAN Registry.

Page 1 of 6




s	Site Number: Physi	Physician Last Name: Dr			
D	Date: / / 2 0 Medic	lata Subject ID:			
1.	Section 1: Treatment Discontinuation 1. Is your patient discontinuing a treatment with this visit? 1 Yes				
2.	2. Which systemic treatment has you	r patient most recently discontinued? Select one.			
	Abiraterone Androgen deprivation (LHRH) Apalutamide Bicalutamide or other anti-and Cabazitaxel Clinical trial Docetaxel Enzalutamide External beam radiation thera Radium-223 Sipuleucel-T Other tumor-directed therapy	lrogen			
3.	3. Does your patient have biochemic	al progression?			
		PSA rise without initial decline on this therapy PSA rise after an initial decline on this therapy			
4.	4. Does your patient have radiograph	ic progression of bone metastases?			
		Increase of existing bone lesion(s) New bone lesion(s) after initially stable lesion(s) New bone lesion(s) on first on-treatment scan			
5.	5. Does your patient have radiograph either <u>increased</u> existing or <u>new</u> le	ic progression of non-bone metastases, sion(s)? Increased New			
	₁ ☐ Yes →₅₃ Which? In both co				
	ь Li c Li d О	/mph nodes 1 □ 2 □ ver 1 □ 2 □ ung 1 □ 2 □ ther 1 □ 2 □ Page 2 of 6 2 □			



Site Number:	Physician Las	st Name: Dr
Date://20	Medidata Sub	ject ID:
2 De 3 Inc 4 An 5 Tu	Select all that appl	y. al event →6b Which? Select all that apply. nce status 1 □ Need for bone radiation n 2 □ Need for bone surgery s 3 □ Pathologic fracture e 4 □ Cord compression
7. Has your patient experien	ced toxicity from	the treatment that he is stopping?
₂	Secondary	Primary Secondary Cardiopulmonary Hypertension 1 □ 2 □ Heart failure 1 □ 2 □ Myocardial infarction 1 □ 2 □ Pheumonitis 1 □ 2
e Libido decreased 1 f Infection 1 Neurologic g Cognitive disturbance 1 h Neuropathy 1	2	Dermatologic/Skeletal Osteoporosis
Gastroenterologic i Diarrhea 1	2	Hematologic/Laboratory Hemorrhage 1
	Page 3 o	of 6



S	ite Num	nber: _	- —	Physician Last Name: Dr	
D	ate:	_1	_/20	Medidata Subject ID:	
8.	1 🔲		**************************************	top the treatment significantly influenced by other farmich? Select all that apply. Decrease in quality of life Inconvenience of the therapy (e.g., dosing, logistics) Difficulties with adherence Patient no longer able to afford despite unchanged confinerate in cost or change in insurance Clinical trial enrollment End of scheduled therapy (e.g., chemotherapy cycles of Patient preference to stop because of other factors Difficult patient—physician relation	st
9.		One pr Disea Toxici	imary reasesses progressity (questic	ession (questions 3–6)	
			Plea	ease continue with Section 2 (next page).	
				Page 4 of 6	





Site Number: Physician Last Name: Dr				
Date://20	Medidata Subject ID:			
Section 2: New Treatment Initiation 1. Is your patient starting a new treatment with this visit? 1 Yes Continue with question 2 (below). 2 No End of questionnaire.				
2. Which disease state best describes your patient? Choose one. 1				
3. What are the sites of dise 1 Prostate gland 2 Lymph node metas 3 Bone metastasis 4 Visceral metastasi 5 Other soft tissue m	stasis Mhat visceral metastasis site(s)? Lung Liver Adrenal glands			
1 .	one testing for genomic alterations? → 4a What type(s)? 1 ☐ Germline DNA 2 ☐ Tumor DNA or RNA 3 ☐ Cell-free/circulating tumor DNA 4 ☐ Circulating tumor cells			
he starting now? In both Abiraterone Androgen deprivate Apalutamide Bicalutamide or othe Cabazitaxel Clinical trial Docetaxel Enzalutamide External beam rade Radium-223 Sipuleucel-T Other cancer-direct	columns, choose all that apply. So far Starting now star			



Site Number: Physician L	nysician Last Name: Dr		
Date: / / 2 0 Medidata Se	ubject ID:		
6. Which factors were most important in your treatment choice? Choose <u>up to five</u> in total.			
Patient factors Age (very young or very old) High symptom burden Low symptom burden	Tumor characteristics 24		
Poor performance status Good performance status Low quality of life High quality of life	Level of PSA (very low or very high) Level of PSA (very low or very high) Genomic testing results Variant histology (e.g., small cell) Poor response to prior therapy Fast rate of disease progression		
Active comorbidities (including side effects of prior therapy) B Diabetes mellitus G Seizures Heart disease Dementia Neuropathy Fatigue Falls Anemia Concomitant medications	Markedly abnormal serum markers (e.g. alk. phosphatase, liver function) Expectations about new treatment Strong effect on prognosis Strong effect on quality of life Favorable side-effect profile Improved adherence New mechanism of action Convenience of administration, dosing, or appointment schedule		
Patient preferences 17	·		
Page 6 of 6			